ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 646

Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) Is a Susceptibility Factor for Early Axial Spa Meeting the ASAS Classification Criteria: Results from the Spondyloarthritis Caught Early and DEvenir des Spondyloarthrites Indifférenciées Récentes Cohorts

Anoek de Koning1, Marjolijn Hameetman2, Corinne Miceli-Richard3, Maxime Dougados4, Désirée van der Heijde5, Fina Kurreeman6 and Floris van Gaalen7, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Department of Rheumatology, Hôpital Bicêtre, Paris, France, 4Department of Rheumatology, Rene Descartes University, Hôpital Cochin, Paris, France, 5Leiden University Medical Center, Leiden, Netherlands, 6Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, Leiden, Netherlands, 7Rheumatology, LUMC, Leiden, Netherlands

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Axial spondyloarthritis and genetics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Genetic research in axSpA is performed in patients with longstanding ankylosing spondylitis (AS). Early axial spondyloarthritis (axSpA) is a diverse patient group in which a minority of the patients have AS. Therefore, it is not known if recently identified genetic risk factors for AS are also risk factors for early axSpA. The aim is to evaluate if ERAP1 and HLA-B*4001 are susceptibility factors for early axSpA.

Methods: Patients with early axSpA meeting the ASAS classification criteria from the SPondyloArthritis Caught Early (SPACE) cohort (inclusion criteria: back pain for ≥3 months, ≤2 years, onset <45 years) and the DEvenir des Spondyloarthrites Indifférenciées Récentes (DESIR) cohort (inclusion criteria: inflammatory back pain for ≥3 months, ≤3 years, age <50) were typed for two well established AS genetic risk factors: ERAP1 SNPs (rs30187 (susceptibility), rs17482078 (protective) and rs10050860 (neutral)1) and HLA-B*4001. Subsequently, for ERAP1 SNPs sub analyses were performed for AS and non-radiographic axSpA (nr-axSpA) patients. Analysis of weaker AS risk factors was limited by sample size. For ERAP1, genotyped Dutch healthy controls (n=1085) (data kindly provided by C. Wijmenga and A. Zhernakova (UMCG)) and published French subjects1 were used as controls. For HLA-B*4001 healthy blood bank donors from the Netherlands (n=5584) and France (n=10177) were used as controls.

Results: In 486 DESIR patients (mean age 32.5 (SD 8.6); 50% male; 84% HLA-B27+; 18% X-SI+) and 144 SPACE patients (mean age 29.5 (SD 8); 51% male; 88% HLA-B27+; 24% X-SI+) ERAP1 SNP rs30187 was more common than in controls (OR 1.2, p=0.01 in meta-analysis; table 1). rs17482078 and rs10050860 were negatively associated with early axSpA (both OR 0.7 (0.6-0.9) p<0.01 in meta-analysis). Minor allele frequencies were similar for AS patients and nr-axSpA patients (table 2). Although both cohorts were sufficiently powered, HLA-B*4001 was not positively associated with early axSpA (OR 0.6 (0.4-0.9) in meta-analysis).

Conclusion: ERAP1 rs30187 is a genetic risk factor for early axSpA patients with and without radiographic sacroiliitis. To our knowledge this is the first report of genetic risk factor research in early axSpA patients meeting the ASAS criteria. Larger cohorts are needed to study additional AS risk factors.

 ADDIN EN.REFLIST 1.         Kadi A, Izac B, Said-Nahal R, Leboime A, Van Praet L, de Vlam K, et al. Investigating the genetic association between ERAP1 and spondyloarthritis. Ann Rheum Dis. 2013;72(4):608-13.



Disclosure: A. de Koning, None; M. Hameetman, None; C. Miceli-Richard, None; M. Dougados, None; D. van der Heijde, None; F. Kurreeman, None; F. van Gaalen, None.

To cite this abstract in AMA style:

de Koning A, Hameetman M, Miceli-Richard C, Dougados M, van der Heijde D, Kurreeman F, van Gaalen F. Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) Is a Susceptibility Factor for Early Axial Spa Meeting the ASAS Classification Criteria: Results from the Spondyloarthritis Caught Early and DEvenir des Spondyloarthrites Indifférenciées Récentes Cohorts [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/endoplasmic-reticulum-aminopeptidase-1-erap1-is-a-susceptibility-factor-for-early-axial-spa-meeting-the-asas-classification-criteria-results-from-the-spondyloarthritis-caught-early-and-devenir-des/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/endoplasmic-reticulum-aminopeptidase-1-erap1-is-a-susceptibility-factor-for-early-axial-spa-meeting-the-asas-classification-criteria-results-from-the-spondyloarthritis-caught-early-and-devenir-des/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology